Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 39

1.

Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta-analysis of randomized controlled trials.

Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM.

Medicine (Baltimore). 2017 May;96(21):e6970. doi: 10.1097/MD.0000000000006970.

2.

Very high frequency of fragility fractures associated with high-dose glucocorticoids in postmenopausal women: A retrospective study.

Kageyama G, Okano T, Yamamoto Y, Nishimura K, Sugiyama D, Saegusa J, Tsuji G, Kumagai S, Morinobu A.

Bone Rep. 2016 Nov 17;6:3-8. doi: 10.1016/j.bonr.2016.11.003. eCollection 2017 Jun.

3.

A Novel Hybrid Compound LLP2A-Ale Both Prevented and Rescued the Osteoporotic Phenotype in a Mouse Model of Glucocorticoid-Induced Osteoporosis.

Mohan G, Lay EY, Berka H, Ringwood L, Kot A, Chen H, Yao W, Lane NE.

Calcif Tissue Int. 2017 Jan;100(1):67-79. doi: 10.1007/s00223-016-0195-6. Epub 2016 Sep 27.

PMID:
27679514
4.

Alendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseases: A meta-analysis.

Kan SL, Yuan ZF, Li Y, Ai J, Xu H, Sun JC, Feng SQ.

Medicine (Baltimore). 2016 Jun;95(25):e3990. doi: 10.1097/MD.0000000000003990. Review.

5.

Glucocorticoid-induced osteoporosis.

Briot K, Roux C.

RMD Open. 2015 Apr 8;1(1):e000014. doi: 10.1136/rmdopen-2014-000014. eCollection 2015. Review.

6.

Fracture rate associated with quality metric-based anti-osteoporosis treatment in glucocorticoid-induced osteoporosis.

Overman RA, Gourlay ML, Deal CL, Farley JF, Brookhart MA, Layton JB.

Osteoporos Int. 2015 May;26(5):1515-24. doi: 10.1007/s00198-014-3022-9. Epub 2015 Jan 20.

7.

New strategies for osteoporosis patients previously managed with strontium ranelate.

Vestergaard P.

Ther Adv Musculoskelet Dis. 2014 Dec;6(6):217-25. doi: 10.1177/1759720X14552070. Review.

8.

Medication-induced osteoporosis: screening and treatment strategies.

Panday K, Gona A, Humphrey MB.

Ther Adv Musculoskelet Dis. 2014 Oct;6(5):185-202. doi: 10.1177/1759720X14546350. Review.

9.

Acceptability of bone antiresorptive therapy among HIV-infected adults at different stages of antiretroviral therapy.

Taras J, Arbess G, Owen J, Guiang CB, Tan DH.

Patient Prefer Adherence. 2014 Sep 24;8:1311-6. doi: 10.2147/PPA.S67090. eCollection 2014.

10.

Challenges in implementing and maintaining osteoporosis therapy.

Modi A, Sajjan S, Gandhi S.

Int J Womens Health. 2014 Aug 13;6:759-69. doi: 10.2147/IJWH.S53489. eCollection 2014. Review.

11.

An opportunity for improving osteoporosis treatment in home health care.

Switzer JA, Rolnick SJ, Jackson JM, Schneider NK, Dutkowski JE, Edgett DR.

Geriatr Orthop Surg Rehabil. 2010 Nov;1(2):46-51. doi: 10.1177/2151458510386950.

12.

Clinical role of bisphosphonate therapy.

Hampson G, Fogelman I.

Int J Womens Health. 2012;4:455-69. doi: 10.2147/IJWH.S24783. Epub 2012 Sep 3.

13.

Glucocorticoid-induced osteoporosis and osteonecrosis.

Weinstein RS.

Endocrinol Metab Clin North Am. 2012 Sep;41(3):595-611. doi: 10.1016/j.ecl.2012.04.004. Epub 2012 May 23. Review.

14.

Aging and bone loss: new insights for the clinician.

Demontiero O, Vidal C, Duque G.

Ther Adv Musculoskelet Dis. 2012 Apr;4(2):61-76. doi: 10.1177/1759720X11430858.

15.

Medical treatment of osteoporotic vertebral fractures.

Langdahl BL, Harsløf T.

Ther Adv Musculoskelet Dis. 2011 Feb;3(1):17-29. doi: 10.1177/1759720X10392105.

16.

Glucocorticoid-induced osteoporosis: treatment update and review.

Fraser LA, Adachi JD.

Ther Adv Musculoskelet Dis. 2009 Apr;1(2):71-85. doi: 10.1177/1759720X09343729.

17.

Treatment of glucocorticoid-induced osteoporsis.

Mazziotti G, Giustina A, Canalis E, Bilezikian JP.

Ther Adv Musculoskelet Dis. 2009 Feb;1(1):27-34. doi: 10.1177/1759720X09343222.

18.

Do premenopausal women with major depression have low bone mineral density? A 36-month prospective study.

Cizza G, Mistry S, Nguyen VT, Eskandari F, Martinez P, Torvik S, Reynolds JC, Gold PW, Sinaii N, Csako G; POWER Study Group.

PLoS One. 2012;7(7):e40894. Epub 2012 Jul 27. Erratum in: PLoS One. 2012;7(10). doi:10.1371/annotation/193f2b29-b8b0-41e8-808a-290df5577a53. Sinai, Ninet [corrected to Sinaii, Ninet].

19.

Glucocorticoid-induced osteoporosis - a disorder of mesenchymal stromal cells?

Hardy R, Cooper MS.

Front Endocrinol (Lausanne). 2011 Aug 27;2:24. doi: 10.3389/fendo.2011.00024. eCollection 2011.

20.

Three-year experience with combined treatment with alendronate and alfacalcidol in Japanese patients with severe bone loss and osteoporotic fracture.

Iwamoto J, Sato Y, Uzawa M, Takeda T, Matsumoto H.

Ther Clin Risk Manag. 2011;7:257-64. doi: 10.2147/TCRM.S22167. Epub 2011 Jun 29.

Supplemental Content

Support Center